Ratio Therapeutics, Inc.
Targeted radiopharmaceuticals (small molecule radiotherapeutics with proprietary chelation technology for cancer treatment)
- Sector
- Biotech
- Headquarters
- BOSTON, MA
- Founded
- 2021
- Latest Form D
- $50.7M, Dec 2023
- Total capital
- $50.7M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $50.7M
- 1 Form D · last Dec 2023
- 34 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 14 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$50.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Albert W. HolmanDirectorNamed in SEC Form D filings
- Allan W. GreenDirectorNamed in SEC Form D filings
- Jacob W. HestermanExecutive OfficerNamed in SEC Form D filings
- John W. BabichExecutive Officer, DirectorNamed in SEC Form D filings
- John W. GarveyExecutive OfficerNamed in SEC Form D filings
- John W. HoppinExecutive Officer, DirectorNamed in SEC Form D filings
Show all 11 people
- Matthias W. FriebeExecutive OfficerNamed in SEC Form D filings
- Reed W. MalleckExecutive OfficerNamed in SEC Form D filings
- Scott W. HolbrookDirectorNamed in SEC Form D filings
- Shawn W. HillierExecutive OfficerNamed in SEC Form D filings
- Susan W. WhoriskeyDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 14- PendingFibroblast Activation Protein-targeted Compositions And Methods Of Use ThereofUSPTOApplication 18998265
- PendingFibroblast Activation Protein-targeted Compositions And Methods Of Use ThereofUSPTOApplication PCTUS2025041769
- Pending18F-FLUORINATED Fatty Acids And Uses ThereofUSPTOApplication 18996666
Show all 14 patent records
- Fibroblast Activation Protein-targeted Compositions And Methods Of Use ThereofFeb 5, 2026 · Application 18998265Pending
- Fibroblast Activation Protein-targeted Compositions And Methods Of Use ThereofApplication PCTUS2025041769Pending
- 18F-FLUORINATED Fatty Acids And Uses ThereofApplication 18996666Pending
- Somatostatin Binding Compositions And Methods Of Use ThereofApplication 63715164Pending
- Fibroblast Activation Protein-targeted Compositions And Methods Of Use ThereofApplication 63682520Pending
- Fibroblast Activation Protein-targeted Compositions And Methods Of Use ThereofApplication PCTUS2024039697Pending
- Fibroblast Activation Protein-targeted Compositions And Methods Of Use ThereofApplication 63627309Pending
- Fibroblast Activation Protein-targeted Compositions And Methods Of Use ThereofApplication PCTUS2023028945Pending
- Fibroblast Activation Protein-targeted Compositions And Methods Of Use ThereofApplication 63529522Pending
- 18F-FLUORINATED Fatty Acids And Uses ThereofApplication PCTUS2023028114Pending
- Fibroblast Activation Protein-targeted Compositions And Methods Of Use ThereofApplication 63392899Pending
- Radiolabeled Fatty Acid Compositions For Medical Imaging ApplicationsApplication 63390791Pending
- Somatostatin Binding Compositions And Methods Of Use ThereofApplication PCTUS2025053516Pending
- Fibroblast Activation Protein-targeted Compositions And Methods Of Use ThereofApplication 19504187Pending
Related companies, and why
- LB PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
- Mebias Discovery, Inc.Similar federal contract value in Biotech · null in contracts
- OcuTerra Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- NANOMEDTRIX LLCSimilar federal contract value in Biotech · null in contracts
- Boundless Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Treeline BiosciencesSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .